Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma

Current oncology

L. H. Sehn¹  A. Christofides²  C. Owen³  N. L. Berinstein⁴ 

[1] Centre for Lymphoid Cancer, University of British Columbia,;Impact Medicom Inc;University of Calgary and Foothills Medical Centre;University of Toronto and Odette Cancer Centre, Sunnybrook Health Sciences Centre

关键词: Bruton tyrosine kinase inhibitors;    mantle cell lymphoma;    acalabrutinib;   

DOI  :  10.3747/co.26.4345

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Mantle cell lymphoma (mcl) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed or refractory (r/r) disease have a very poor prognosis. The Bruton tyrosine kinase (btk) inhibitor ibrutinib has proven to be an effective agent for patients with r/r mcl. Although usually well tolerated, ibrutinib can be associated with unique toxicities, requiring discontinuation in some patients. Effective and well-tolerated alternatives to ibrutinib for patients with r/r mcl are therefore needed. Novel btk inhibitors such as acalabrutinib, zanubrutinib, and tirabrutinib are designed to improve on the safety and efficacy of first-generation btk inhibitors such as ibrutinib. Data from single-arm clinical trials suggest that, compared with ibrutinib, second-generation btk inhibitors have comparable efficacy and might have a more favourable toxicity profile. Those newer btk inhibitors might therefore provide a viable treatment option for patients with r/r mcl.

【 授权许可】

Unknown